Goose,
You probably also know that George and I have welcomed many well structured arguments and well intentioned questions. In the case of RobertS it seems, to me anyway, his intent is to grab at the slightest thing, and twist it into an attempt to discredit Xoma. Think about it, a Bayer AG news release that talks about novel drugs and therapeutics to attack sepsis is somehow a discredit to Xoma? That is really a stretch. As I stated, Neuprex is a potential new and novel approach to treating sepsis and septic shock. I presume anyone taking the time to study sepsis and septic shock would know of the potential competitive products. While I feel these products are at least three years behind Xoma's Neuprex, Bayer AG is a mature organization, they would naturally be looking forward for other therapeutics, not just in sepsis, but in many other areas as well. To reason that because Bayer is looking for novel therapeutics and conclude that Xoma is left in the lurch is like saying 2+2=1. IMO. And RobertS knows it.
PS..George, thanks for that vote of confidence???? |
